Multiple regulatory pathways of vascular permeability factor/vascular endothelial growth factor (VPF/VEGF) expression in tumors.

VPF/VEGF is a multi-functional cytokine with important roles in both vasculogenesis and angiogenesis. Its production is generally regulated by local oxygen concentration. Hypoxia stimulates VPF/VEGF production by increasing its gene transcription and the stability of its mRNA. The increase in transcription in hypoxia occurs mainly through the stabilization and activation of the transcription factor, Hypoxia Inducible Factor (HIF). Cellular oxygen concentration is not the only regulator of VPF/VEGF synthesis. Some cancer cells can produce high levels of VPF/VEGF even in normoxia. Clear cell renal carcinoma cell line (RCC) like 786-0, pancreatic carcinoma cell line, ASPC-1, fibrocarcinoma cell line, HT1080, ovarian cancer cells, etc. produce an elevated level of VPF/VEGF, which is not dependent on hypoxia. In this article, we discuss different regulatory pathways in tumor cells comprised of oncogenes, tumor suppressor genes etc. that play important roles, in both the transcription and stability of VPF/VEGF mRNA.

[1]  J. Gutkind,et al.  MAPK and Akt act cooperatively but independently on hypoxia inducible factor-1alpha in rasV12 upregulation of VEGF. , 2001, Biochemical and biophysical research communications.

[2]  A. Harris,et al.  Effects of ras and von Hippel-Lindau (VHL) gene mutations on hypoxia-inducible factor (HIF)-1alpha, HIF-2alpha, and vascular endothelial growth factor expression and their regulation by the phosphatidylinositol 3'-kinase/Akt signaling pathway. , 2001, Cancer research.

[3]  L. Nabors,et al.  HuR, a RNA stability factor, is expressed in malignant brain tumors and binds to adenine- and uridine-rich elements within the 3' untranslated regions of cytokine and angiogenic factor mRNAs. , 2001, Cancer research.

[4]  M. Goldberg,et al.  Regulation of vascular endothelial growth factor in cardiac myocytes. , 1995, Circulation research.

[5]  Y. Fujii‐Kuriyama,et al.  Molecular mechanisms of transcription activation by HLF and HIF1α in response to hypoxia: their stabilization and redox signal‐induced interaction with CBP/p300 , 1999, The EMBO journal.

[6]  D. Mukhopadhyay,et al.  Hypoxic induction of human vascular endothelial growth factor expression through c-Src activation , 1995, Nature.

[7]  M. Benezra,et al.  Thrombin-induced release of active basic fibroblast growth factor-heparan sulfate complexes from subendothelial extracellular matrix. , 1993, Blood.

[8]  W. Linehan,et al.  Germline mutations in the von Hippel–Lindau disease tumor suppressor gene: Correlations with phenotype , 1995, Human mutation.

[9]  W. Linehan.  Molecular Genetics of Sporadic and Familial Renal Cell Carcinoma , 2000 .

[10]  G. Martiny-Baron,et al.  Reversion of deregulated expression of vascular endothelial growth factor in human renal carcinoma cells by von Hippel-Lindau tumor suppressor protein. , 1996, Cancer research.

[11]  D. Donner,et al.  Induction of Vascular Endothelial Growth Factor by Insulin-like Growth Factor 1 in Colorectal Carcinoma* , 1996, The Journal of Biological Chemistry.

[12]  Joe W. Gray,et al.  PIK3CA is implicated as an oncogene in ovarian cancer , 1999, Nature Genetics.

[13]  O. Kozawa,et al.  Incadronate Amplifies Prostaglandin F2α-induced Vascular Endothelial Growth Factor Synthesis in Osteoblasts , 2003, Journal of Biological Chemistry.

[14]  J. Caro,et al.  Absolute requirement of aryl hydrocarbon receptor nuclear translocator protein for gene activation by hypoxia. , 1996, Archives of biochemistry and biophysics.

[15]  L. Huang,et al.  Molecular mechanism of hypoxia-inducible factor 1alpha -p300 interaction. A leucine-rich interface regulated by a single cysteine. , 2001, The Journal of biological chemistry.

[16]  Goldman,et al.  Epidermal growth factor stimulates vascular endothelial growth factor production by human malignant glioma cells: a model of glioblastoma multiforme pathophysiology. , 1993, Molecular biology of the cell.

[17]  G. Semenza,et al.  Hypoxia-inducible factor 1 levels vary exponentially over a physiologically relevant range of O2 tension. , 1996, The American journal of physiology.

[18]  D. Mukhopadhyay,et al.  Role of Protein Kinase Cζ in Ras-mediated Transcriptional Activation of Vascular Permeability Factor/Vascular Endothelial Growth Factor Expression* , 2001, The Journal of Biological Chemistry.

[19]  M. Neeman,et al.  Induction of vascular endothelial growth factor expression by hypoxia and by glucose deficiency in multicell spheroids: implications for tumor angiogenesis. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[20]  D. Mukhopadhyay,et al.  Wild-type p53 and v-Src exert opposing influences on human vascular endothelial growth factor gene expression. , 1995, Cancer research.

[21]  J. Folkman,et al.  Fighting cancer by attacking its blood supply. , 1996, Scientific American.

[22]  Michael I. Wilson,et al.  C. elegans EGL-9 and Mammalian Homologs Define a Family of Dioxygenases that Regulate HIF by Prolyl Hydroxylation , 2001, Cell.

[23]  W. Kolch,et al.  Mutant p53 potentiates protein kinase C induction of vascular endothelial growth factor expression. , 1994, Oncogene.

[24]  A. Levy,et al.  A 40-bp RNA Element That Mediates Stabilization of Vascular Endothelial Growth Factor mRNA by HuR* , 2002, The Journal of Biological Chemistry.

[25]  Donglei Zhang,et al.  Vascular endothelial growth factor C expression and lymph node metastasis are regulated by the type I insulin-like growth factor receptor. , 2003, Cancer research.

[26]  K. Tory,et al.  Molecular genetic investigations of the mechanism of tumourigenesis in von Hippel-Lindau disease: analysis of allele loss in VHL tumours , 2004, Human Genetics.

[27]  T. Uchida,et al.  Genomic instability of microsatellite repeats and mutations of H-, K-, and N-ras, and p53 genes in renal cell carcinoma. , 1994, Cancer research.

[28]  P. Ratcliffe,et al.  Oxygen-regulated and Transactivating Domains in Endothelial PAS Protein 1: Comparison with Hypoxia-inducible Factor-1α* , 1999, The Journal of Biological Chemistry.

[29]  J. Rhim,et al.  Activated H-ras oncogenes in human kidney tumors. , 1988, Cancer research.

[30]  J. Gnarra,et al.  Identification of the von Hippel-Lindau disease tumor suppressor gene. , 1993, Science.

[31]  J. Folkman,et al.  Tumor angiogenesis and metastasis--correlation in invasive breast carcinoma. , 1991, The New England journal of medicine.

[32]  L. Ellis,et al.  Regulation of hypoxia-inducible factor-1alpha, vascular endothelial growth factor, and angiogenesis by an insulin-like growth factor-I receptor autocrine loop in human pancreatic cancer. , 2003, The American journal of pathology.

[33]  F. Ismail-Beigi,et al.  Regulation of glut1 mRNA by Hypoxia-inducible Factor-1 , 2001, The Journal of Biological Chemistry.

[34]  E. Keshet,et al.  Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis , 1992, Nature.

[35]  A. Levy,et al.  Hypoxic Stabilization of Vascular Endothelial Growth Factor mRNA by the RNA-binding Protein HuR* , 1998, The Journal of Biological Chemistry.

[36]  R Pingitore,et al.  Neoangiogenesis in colon cancer: correlation between vascular density, vascular endothelial growth factor (VEGF) and p53 protein expression. , 2002, Oncology reports.

[37]  W. Kaelin,et al.  The von Hippel-Lindau tumor suppressor gene. , 2001, Experimental cell research.

[38]  M. Ivan,et al.  HIFα Targeted for VHL-Mediated Destruction by Proline Hydroxylation: Implications for O2 Sensing , 2001, Science.

[39]  C. Kwak,et al.  Thrombospondin‐1, vascular endothelial growth factor expression and their relationship with p53 status in prostate cancer and benign prostatic hyperplasia , 2002, BJU international.

[40]  R. Kaufmann,et al.  Increased Sp1 phosphorylation as a mechanism of hepatocyte growth factor (HGF/SF)-induced vascular endothelial growth factor (VEGF/VPF) transcription , 2003, Journal of Cell Science.

[41]  M. Longaker,et al.  Regulation of Vascular Endothelial Growth Factor Expression in Cultured Keratinocytes. , 1995, The Journal of Biological Chemistry.

[42]  G. Schinzari,et al.  Expression of vascular endothelial growth factor, mitogen-activated protein kinase and p53 in human colorectal cancer. , 2002, Anticancer research.

[43]  B. Zbar,et al.  Molecular analysis of de novo germline mutations in the von Hippel-Lindau disease gene. , 1995, Human molecular genetics.

[44]  K. W. Kim,et al.  Insulin-like growth factor II induced by hypoxia may contribute to angiogenesis of human hepatocellular carcinoma. , 1998, Cancer research.

[45]  Christopher J Schofield,et al.  Hypoxia-inducible Factor (HIF) Asparagine Hydroxylase Is Identical to Factor Inhibiting HIF (FIH) and Is Related to the Cupin Structural Family* , 2002, The Journal of Biological Chemistry.

[46]  J. Mamputu,et al.  Advanced glycation end products increase, through a protein kinase C-dependent pathway, vascular endothelial growth factor expression in retinal endothelial cells. Inhibitory effect of gliclazide. , 2002, Journal of diabetes and its complications.

[47]  D. Peet,et al.  Asparagine Hydroxylation of the HIF Transactivation Domain: A Hypoxic Switch , 2002, Science.

[48]  J. Caro,et al.  Hypoxia-inducible factor 1alpha (HIF-1alpha) protein is rapidly degraded by the ubiquitin-proteasome system under normoxic conditions. Its stabilization by hypoxia depends on redox-induced changes. , 1997, The Journal of biological chemistry.

[49]  N. Yang,et al.  The oncogene phosphatidylinositol 3'-kinase catalytic subunit alpha promotes angiogenesis via vascular endothelial growth factor in ovarian carcinoma. , 2003, Cancer research.

[50]  G. Gillespie,et al.  Vascular endothelial growth factor in human glioma cell lines: induced secretion by EGF, PDGF-BB, and bFGF. , 1995, Journal of Neurosurgery.

[51]  H. Esumi,et al.  Regulation of vascular endothelial growth factor expression by insulin‐like growth factor‐I in endometrial adenocarcinoma cells , 2000, International journal of cancer.

[52]  T. Sugiyama,et al.  Frequent overexpression of vascular endothelial growth factor gene in human renal cell carcinoma. , 1994, The Tohoku journal of experimental medicine.

[53]  B. Spiegelman,et al.  Vascular endothelial growth factor. Regulation by cell differentiation and activated second messenger pathways. , 1992, The Journal of biological chemistry.

[54]  R. Hurta,et al.  Growth factor‐mediated altered expression and regulation of S‐adenosylmethionine decarboxylase in a H‐ras transformed cell line capable of malignant progression , 2002, Journal of cellular biochemistry.

[55]  S. White,et al.  HIF-1α binding to VHL is regulated by stimulus-sensitive proline hydroxylation , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[56]  M. Klagsbrun,et al.  Extracellular matrix‐resident basic fibroblast growth factor: Implication for the control of angiogenesis , 1991, Journal of cellular biochemistry.

[57]  G. Semenza,et al.  Activation of vascular endothelial growth factor gene transcription by hypoxia-inducible factor 1 , 1996, Molecular and cellular biology.

[58]  S. Peltz,et al.  Regulated ARE-mediated mRNA decay in Saccharomyces cerevisiae. , 2001, Molecular cell.

[59]  M. Goldberg,et al.  Post-transcriptional Regulation of Vascular Endothelial Growth Factor by Hypoxia (*) , 1996, The Journal of Biological Chemistry.

[60]  L. Aiello,et al.  Stretch-induced Retinal Vascular Endothelial Growth Factor Expression Is Mediated by Phosphatidylinositol 3-Kinase and Protein Kinase C (PKC)-ζ but Not by Stretch-induced ERK1/2, Akt, Ras, or Classical/Novel PKC Pathways* , 2002, The Journal of Biological Chemistry.

[61]  C. Staley,et al.  Decreased tumorigenicity of a human colon adenocarcinoma cell line by an antisense expression vector specific for c-Src. , 1997, Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research.

[62]  K. Miura,et al.  Vascular endothelial growth factor (VEGF) expression correlates with p53 and ki-67 expressions in tongue squamous cell carcinoma. , 2002, Anticancer research.

[63]  C. Wykoff,et al.  The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis , 1999, Nature.

[64]  A. Knox,et al.  Human airway smooth muscle cells secrete vascular endothelial growth factor: up‐regulation by bradykinin via a protein kinase C and prostanoid‐dependent mechanism , 2001, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[65]  G. Semenza,et al.  Regulation of tumor angiogenesis by p53-induced degradation of hypoxia-inducible factor 1alpha. , 2000, Genes & development.

[66]  W. Kaelin,et al.  Negative regulation of hypoxia-inducible genes by the von Hippel-Lindau protein. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[67]  J. Bishop.  Molecular themes in oncogenesis , 1991, Cell.

[68]  P. Bushel,et al.  Insulin-like growth factor-1 inscribes a gene expression profile for angiogenic factors and cancer progression in breast epithelial cells. , 2002, Neoplasia.

[69]  Eamonn R. Maher,et al.  Hypoxia Inducible Factor-α Binding and Ubiquitylation by the von Hippel-Lindau Tumor Suppressor Protein* , 2000, The Journal of Biological Chemistry.

[70]  Georg Breier,et al.  Vascular endothelial growth factor is a potential tumour angiogenesis factor in human gliomas in vivo , 1992, Nature.

[71]  Klaus Resch,et al.  The p38 MAP kinase pathway signals for cytokine‐induced mRNA stabilization via MAP kinase‐activated protein kinase 2 and an AU‐rich region‐targeted mechanism , 1999, The EMBO journal.

[72]  H. Dvorak,et al.  Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid. , 1983, Science.

[73]  H. Wallerand,et al.  Protein kinase C signalling pathway is involved in the regulation of vascular endothelial growth factor expression in human bladder transitional carcinoma cells. , 2001, Cellular signalling.

[74]  D. Mukhopadhyay,et al.  Central role of p53 on regulation of vascular permeability factor/vascular endothelial growth factor (VPF/VEGF) expression in mammary carcinoma. , 2001, Cancer research.

[75]  G. Semenza,et al.  HER2 (neu) Signaling Increases the Rate of Hypoxia-Inducible Factor 1α (HIF-1α) Synthesis: Novel Mechanism for HIF-1-Mediated Vascular Endothelial Growth Factor Expression , 2001, Molecular and Cellular Biology.

[76]  D. Marmé,et al.  Both v-Ha-Ras and v-Raf Stimulate Expression of the Vascular Endothelial Growth Factor in NIH 3T3 Cells (*) , 1995, The Journal of Biological Chemistry.

[77]  G. Neufeld,et al.  Oncogenic transformation induces tumor angiogenesis: a role for PAR1 activation , 2003, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[78]  E. Manseau,et al.  Increased expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in kidney and bladder carcinomas. , 1993, The American journal of pathology.

[79]  L. Schmidt,et al.  Suppression of growth of renal carcinoma cells by the von Hippel-Lindau tumor suppressor gene. , 1995, Cancer research.

[80]  H. Burger,et al.  Characterization of a human multilineage-colony-stimulating factor cDNA clone identified by a conserved noncoding sequence in mouse interleukin-3. , 1987, Gene.

[81]  Lars Holmgren,et al.  Dormancy of micrometastases: Balanced proliferation and apoptosis in the presence of angiogenesis suppression , 1995, Nature Medicine.

[82]  W. Risau,et al.  Mechanisms of angiogenesis , 1997, Nature.

[83]  S. McKnight,et al.  A Conserved Family of Prolyl-4-Hydroxylases That Modify HIF , 2001, Science.

[84]  R. Kerbel,et al.  Mutant ras oncogenes upregulate VEGF/VPF expression: implications for induction and inhibition of tumor angiogenesis. , 1995, Cancer research.

[85]  S. Capaccioli,et al.  A conserved AU‐rich element in the 3’ untranslated region of bcl‐2 mRNA is endowed with a destabilizing function that is involved in bcl‐2 down‐regulation during apoptosis , 2000, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[86]  D. Mukhopadhyay,et al.  The von Hippel-Lindau tumor suppressor gene product interacts with Sp1 to repress vascular endothelial growth factor promoter activity , 1997, Molecular and cellular biology.

[87]  R. Weinberg,et al.  Tumor suppressor genes. , 1991, Science.

[88]  D. Ribatti,et al.  Bcl-2 Overexpression in Human Melanoma Cells Increases Angiogenesis through Vegf Mrna Stabilization and Hif-1-mediated Transcriptional Activity , 2002, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[89]  M. Ferguson-Smith,et al.  Somatic mutations of the von Hippel-Lindau disease tumour suppressor gene in non-familial clear cell renal carcinoma. , 1994, Human molecular genetics.

[90]  L. Poellinger,et al.  Redox-Regulated Recruitment of the Transcriptional Coactivators CREB-Binding Protein and SRC-1 to Hypoxia-Inducible Factor 1α , 2000, Molecular and Cellular Biology.

[91]  E. Keystone,et al.  Mutant p53 in bone marrow stromal cells increases VEGF expression and supports leukemia cell growth. , 2003, Experimental hematology.

[92]  M. Lerman,et al.  Identification of intragenic mutations in the von Hippel-Lindau disease tumour suppressor gene and correlation with disease phenotype. , 1994, Human molecular genetics.

[93]  H. Dvorak,et al.  Vascular permeability factor (vascular endothelial growth factor) gene is expressed differentially in normal tissues, macrophages, and tumors. , 1992, Molecular biology of the cell.

[94]  D. Livingston,et al.  Activation of Hypoxia-inducible Transcription Factor Depends Primarily upon Redox-sensitive Stabilization of Its α Subunit* , 1996, The Journal of Biological Chemistry.

[95]  M. Olah,et al.  Distinct Protein Kinase C Isoforms Mediate Regulation of Vascular Endothelial Growth Factor Expression by A2A Adenosine Receptor Activation and Phorbol Esters in Pheochromocytoma PC12 Cells* , 2003, The Journal of Biological Chemistry.

[96]  T. Shuin,et al.  Somatic mutations of the von Hippel-Lindau tumor suppressor gene in sporadic central nervous system hemangioblastomas. , 1994, Cancer research.

[97]  D. Hanahan,et al.  Induction of angiogenesis during the transition from hyperplasia to neoplasia , 1989, Nature.

[98]  M. Goldberg,et al.  Transcriptional Regulation of the Rat Vascular Endothelial Growth Factor Gene by Hypoxia (*) , 1995, The Journal of Biological Chemistry.

[99]  Y. Joo,et al.  Expression of Vascular Endothelial Growth Factor and p53 in Pancreatic Carcinomas , 2002, The Korean journal of internal medicine.

[100]  M. Lush,et al.  Detailed genetic mapping of the von Hippel-Lindau disease tumour suppressor gene. , 1993, Journal of medical genetics.

[101]  A. Giaccia,et al.  Induction of vascular endothelial growth factor by hypoxia is modulated by a phosphatidylinositol 3-kinase/Akt signaling pathway in Ha-ras-transformed cells through a hypoxia inducible factor-1 transcriptional element. , 1997, Blood.

[102]  J. M. Arbeit,et al.  Coordinate up-regulation of hypoxia inducible factor (HIF)-1alpha and HIF-1 target genes during multi-stage epidermal carcinogenesis and wound healing. , 2000, Cancer research.

[103]  H. Dvorak,et al.  A highly conserved vascular permeability factor secreted by a variety of human and rodent tumor cell lines. , 1986, Cancer research.

[104]  D. Mukhopadhyay,et al.  Requirement of different signaling pathways mediated by insulin-like growth factor-I receptor for proliferation, invasion, and VPF/VEGF expression in a pancreatic carcinoma cell line. , 2003, Biochemical and biophysical research communications.

[105]  G. Semenza.  HIF-1 and mechanisms of hypoxia sensing. , 2001, Current opinion in cell biology.

[106]  M. Goldberg,et al.  Hypoxia-inducible Protein Binding to Vascular Endothelial Growth Factor mRNA and Its Modulation by the von Hippel-Lindau Protein* , 1996, The Journal of Biological Chemistry.